**Alzheimer’s Drug Discovery – Drug Development RFP \*and\* Neuroimaging and CSF Biomarker Development \*and\* Prevention Beyond the Pipeline \*and\* Program to Accelerate Clinical Trials (PACT) RFP**

*Unrestricted funding opportunity*

**Coordinator:** Jessica McDaniel, Sr. Director, Foundation Relations, (Jessica.McDaniel@emory.edu)

**Website:** <https://www.alzdiscovery.org/research-and-grants/funding-opportunities>

**Submission Limitations:** None, however, Please contact your RAS unit \*and\* Jessica McDaniel to inform them of your intent to submit

**Foundation LOI Deadline:** **July 10, 2020, 5:00 PM (EST)**

**Opportunity** **Details**: The Alzheimer's Drug Discovery Foundation (ADDF) supports promising research projects from around the world to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias. The goal is to accelerate the development of therapies through four core areas: Drug discovery, Clinical trials, Biomarkers, and Prevention. The ADDF is interested in novel therapeutic approaches, including small molecules, biologics, and gene therapies. Because the mechanisms underlying Alzheimer's disease and related dementias are varied and complex, ADDF maintains a diverse portfolio of drug targets.

Four funding opportunities are currently open:

[Drug Development Program](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program): The goal of this RFP is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years. Specifically, the Drug Development RFP supports: 1) Preclinical pharmacokinetics, pharmacodynamics, target engagement, and preliminary rodent tolerability 2) *In* *vivo* efficacy or proof-of-concept studies. Average Award up to $600,000 based on stage and scope of research.

[Neuroimaging and CSF Biomarker Development Program](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers): The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Specifically, this RFP focuses on: developing novel PET ligands for clinical use, supporting novel CSF biomarkers, validating established MRI approaches in larger cohorts. Peripheral biofluids and digital approaches are supported through the [**Diagnostics Accelerator RFP**](https://www.alzdiscovery.org/research-and-grants/diagnostics-accelerator). Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include: Neuronal loss, Vascular injury and blood-brain barrier integrity, Mitochondria and metabolic function, Protein misfolding/proteostasis, Oxidative stress, White matter changes. Average Award up to $600,000 based on stage and scope of research.

[Prevention Beyond the Pipeline:](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline)  The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline RFP supports: 1) Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA):  2) Comparative Effectiveness Research: 3) Studies of Cognitive Decline and Cognitive Reserve: Average Award $50,000 -$100,000 for epidemiological analysis and up to $3,000,000 for clinical trials based on stage and scope of research.

[Program to Accelerate Clinical Trials (PACT) RFP](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact): The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. This includes novel, repurposed, and repositioned drugs as well as natural products. Specifically, the PACT RFP supports: 1) Early-stage human clinical trials, 2) Regulatory studies. The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Average Award up to $3,000,000 based on stage and scope of research.

**Eligibility**: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits - Industry partnerships are strongly encouraged - and biotechnology companies.

**Application Components**: Submit the LOI through the ADDF Funding Portal: <https://addf.fluxx.io/user_sessions/new> Along with contact and project information, the LOI will include: Scientific Rationale and Background (300 words maximum), Specific Aims (300 words maximum), and Summary of Key Supporting Data (300 words maximum).

**Proposal:** After your LOI is submitted, it will be reviewed to evaluate whether the proposed project is consistent with the mission and funding priorities of the ADDF. Only invited full proposals will be accepted.

For more information please visit: <https://www.alzdiscovery.org/research-and-grants/funding-opportunities>